Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392866 | 0.74 | CNR2 (0.44) | TSHRKDM4EALDH1A1RECQLNPC1 | |
| SCHEMBL3301737 | 0.71 | RECQL (0.35) | TSHRRECQLSMN1; SMN2RAB9AKCNK3 | |
| SCHEMBL17275417 | 0.69 | APLNR (0.37) | TSHRKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL17275444 | 0.66 | CNR2 (0.36) | CNR2 | |
| SCHEMBL21813723 | 0.65 | — | — | |
| SCHEMBL15664234 | 0.65 | — | — | |
| SCHEMBL15664030 | 0.65 | — | — | |
| SCHEMBL1436203 | 0.65 | — | — | |
| SCHEMBL16486922 | 0.63 | CTSA (0.36) | — | |
| SCHEMBL12862796 | 0.63 | KDM4E (0.39) | TSHRKDM4EALDH1A1RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | TSHR 2302/4885KDM4E 1437/4885ALDH1A1 3887/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | TSHR 2302/4885KDM4E 1437/4885ALDH1A1 3887/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | TSHR 2302/4885KDM4E 1437/4885ALDH1A1 3887/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | TSHR 2302/4885KDM4E 1437/4885ALDH1A1 3887/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | TSHR 2302/4885KDM4E 1437/4885ALDH1A1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.